Blar i NTNU Open på forfatter "Sexton, Joseph"
-
Discontinuation rate of sulfasalazine, leflunomide and methotrexate due to adverse events in a real-life setting (NOR-DMARD)
Pawel, Mielnik; Sexton, Joseph; Fagerli, Karen Minde; Bakland, Gunnstein; Hu, Yi; Kristianslund, Eirik; Hoff, Mari; Wierød, Ada; Kvien, Tore Kristian Aaserud (Peer reviewed; Journal article, 2023)Objectives MTX, LEF and SSZ are conventional synthetic DMARDs (csDMARDs) with a well-established role in the treatment of RA. We aimed to estimate and compare the relative risks for adverse events (AEs) and the ... -
Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial
Syversen, Silje Watterdal; Goll, Guro Løvik; Jørgensen, Kristin Kaasen; Sandanger, Øystein; Sexton, Joseph; Olsen, Inge Christoffer; Gehin, Johanna Elin; Warren, David; Brun, Marthe Kirkesæther; Klaasen, Rolf; Karlsen, Lars Normann; Noraberg, Geir; Zettel, Camilla; Ljoså, Maud-Kristine Aga; Haugen, Anne Julsrud; Njålla, Rune Johan; Bruun, Trude J; Seeberg, Kathrine; Michelsen, Brigitte; Strand, Eldri Kveine; Skorpe, Svanaug; Blomgren, Ingrid; Bragnes, Yngvill; Dotterud, Christian; Thune, Turid Jorunn; Ystrøm, Carl Magnus; Torp, Roald; Pawel, Mielnik; Mørk, Cato; Kvien, Tore Kristian; Jahnsen, Jørgen; Bolstad, Nils; Haavardsholm, Espen A. (Peer reviewed; Journal article, 2021)Importance: Proactive therapeutic drug monitoring (TDM), defined as individualized drug dosing based on scheduled monitoring of serum drug levels, has been proposed as an alternative to standard therapy to maximize efficacy ... -
Health-related quality of life in patients with psoriatic and rheumatoid arthritis: Data from the prospective multicentre NOR-DMARD study compared with Norwegian general population controls
Michelsen, Brigitte; Uhlig, Till; Sexton, Joseph; Heijde, Desirée van der; Hammer, Hilde Berner; Kristianslund, Eirik; Wierød, Ada; Bakland, Gunnstein; Rødevand, Erik; Krøll, Frode; Loge, Jon Håvard; Haugeberg, Glenn; Kvien, Tore Kristian (Journal article; Peer reviewed, 2018)Objectives To compare (1) Short Form-36 (SF-36) Physical Component Summary (PCS) and Mental Component Summary (MCS), scale scores and Short Form-6 dimensions (SF-6D) between patients with rheumatoid arthritis (RA) and ... -
Long‐term efficacy and safety of biosimilar infliximab (CT‐P13) after switching from originator infliximab: Open‐label extension of the NOR‐SWITCH trial
Goll, Guro Løvik; Jørgensen, Kristin Kaasen; Sexton, Joseph; Olsen, Inge Christoffer; Bolstad, Nils; Haavardsholm, Espen A.; Lundin, Knut Erik Aslaksen; Tveit, Kåre Steinar; Lorentzen, Merete; Berset, Ingrid Prytz; Fevang, Bjørg-Tilde Svanes; Kalstad, Synnøve; Ryggen, Kristin; Warren, David; Klaasen, Rolf; Asak, Øivind Wessel; Baigh, Somyeh; Blomgren, Ingrid; Brenna, Øystein; Bruun, Trude J; Dvergsnes, Katrine; Frigstad, Svein Oskar; Myrnes, Inger; Hatten, Ingvild Helgheim; Huppertz-Hauss, Gert; Henriksen, Magne; Hoie, Sunniva S.; Krogh, Jan Reidar; Midtgard, Irina P.; Mielnik, Pawel; Moum, Bjørn; Noraberg, Geir; Poyan, Armin; Prestegård, Ulf; Rashid, Haroon Ur; Strand, Eldri Kveine; Skjetne, Kristine; Seeberg, Kathrine; Torp, Roald; Ystrøm, Carl Magnus; Vold, Cecilia; Zettel, Camilla C.; Waksvik, Kenneth; Gulbrandsen, Bjørn; Hagfors, Jon; Mørk, Cato; Jahnsen, Jørgen; Kvien, Tore Kristian (Journal article; Peer reviewed, 2019)Background and objectives The 52‐week, randomized, double‐blind, noninferiority, government‐funded NOR‐SWITCH trial demonstrated that switching from infliximab originator to less expensive biosimilar CT‐P13 was not ...